Alternative delivery methods under development have so far failed to live up to expectations. In many cases the technical difficulties associated with the delivery technique have not been overcome, leading to a return to injection based therapies. Big Pharma have all but exited the development of new insulin therapies leaving the field to small niche players.
Scope
- Comprehensive analysis of the current insulin antidiabetic pipeline detailing the broad range of developmental classes.
- A detailed clinical and commercial assessment of all key emerging therapies.
- Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2017.
Highlights of this title
Interest in inhaled insulin candidates has dropped significantly since 2007. Questions over reimbursement, social acceptability, pulmonary function and a potential lung cancer signal have led to the leading insulin companies cancelling their inhaled insulin programs
The insulin antidiabetic pipeline is mainly focused on new drug delivery methodologies rather than developing new injection based therapies. 76% of the pipeline is non-injection based therapies
Small companies dominate the pipeline with Big Pharma almost absent. Of the top twenty pharmaceutical companies only Abbott has an insulin candidate
Key reasons to purchase this title
- Quantify the future drugs in the insulin antidiabetic market.
- Identify licensing opportunities based on company portfolio and market needs.
- Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs.
